PBAC's latest decision on Hydroxyethyl starch 130/0.4: Recommended with restriction (2009). Considered for Plasma volume expander for the treatment and prophylaxis of hypovolaemia, as an alternative to succinylated gelatin (Gelofusine).
PBAC outcome
Recommended with restriction
Unrestricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2009
Submissions
1
2009 → 2009
Eligible population
patients undergoing cardiac (three trials), abdominal (three trials), major orthopaedic (one trial) or paediatric (one trial) surgery
Therapy area
Other
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Surrogate | Other
Key trials
Boldt et al, Haas et al, Haisch et al, Mahmood et al, Mittermayr et al, Boks et al, Godet et al, Van der Linden et al, Witt et al, Yap et al
Comparator
succinylated gelatin (Gelofusine) I.V. infusion
Economic model
Cost-minimisation
ICER note
Cost minimisation analysis performed; no ICER calculated